Research ExplorerPublicationsA phase II study of irinotecan (CPT-11) and carboplatin in p...

A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).

Standard

A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC). / Laack, Eckart; Thoem, Ina; Krüll, Andreas; Engel-Riedel, Walburga; Müller, Thomas; Meissner, Christoph; Dürk, Heinz; Fischer, Jürgen; Gütz, Sylvia; Kortsik, Cornelius; Elbers, Matthias; Schuch, Gunter; Andritzky, Birte; Görn, Michael; Burkholder, Iris; Edler, Lutz; Hossfeld, Dieter Kurt; Bokemeyer, Carsten.

In: LUNG CANCER, Vol. 57, No. 2, 2, 2007, p. 181-186.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Laack, E, Thoem, I, Krüll, A, Engel-Riedel, W, Müller, T, Meissner, C, Dürk, H, Fischer, J, Gütz, S, Kortsik, C, Elbers, M, Schuch, G, Andritzky, B, Görn, M, Burkholder, I, Edler, L, Hossfeld, DK & Bokemeyer, C 2007, 'A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).', LUNG CANCER, vol. 57, no. 2, 2, pp. 181-186. <http://www.ncbi.nlm.nih.gov/pubmed/17442447?dopt=Citation>

APA

Laack, E., Thoem, I., Krüll, A., Engel-Riedel, W., Müller, T., Meissner, C., Dürk, H., Fischer, J., Gütz, S., Kortsik, C., Elbers, M., Schuch, G., Andritzky, B., Görn, M., Burkholder, I., Edler, L., Hossfeld, D. K., & Bokemeyer, C. (2007). A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC). LUNG CANCER, 57(2), 181-186. [2]. http://www.ncbi.nlm.nih.gov/pubmed/17442447?dopt=Citation

Vancouver

Laack E, Thoem I, Krüll A, Engel-Riedel W, Müller T, Meissner C et al. A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC). LUNG CANCER. 2007;57(2):181-186. 2.

Bibtex

@article{7eadafdd9a2a4b2f991f4ad6e0abd6b1,
title = "A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).",
abstract = "PURPOSE: The aim of this phase II trial was to evaluate the efficacy and safety of a combination chemotherapy containing irinotecan (CPT-11) and carboplatin as first-line treatment of patients with small cell lung cancer (SCLC). PATIENTS AND METHODS: From December 2002 to May 2004 61 patients with limited disease (IASLC classification) were enrolled who were not suitable for concurrent chemo-radiotherapy. Eighteen of the 61 patients (29.5%) had malignant pleural or pericardial effusion and 4 patients (6.6%) had involved supra- or infraclavicular lymph nodes. Patients received irinotecan 50mg/m(2) on days 1, 8 and 15 and carboplatin AUC 5 on day 1, every 4 weeks. RESULTS: A total of 233 chemotherapy cycles were administered. The median number of cycles per patient was 4. The overall response rate to chemotherapy on an intention-to-treat basis was 64%. The median overall survival was 13.8 months, the median disease-free survival 8.0 months, the 1-year survival rate 53.5%, and the 2-year survival rate 17.9%. Haematological and non-hematogical toxicities were low (CTC-grade 3 neutropenia 14.8%, grade 3 thrombocytopenia 5.2%, grade 3/4 anemia 5.1%, grade 3 nausea/vomiting 5.1%, grade 3 diarrhea 3.6%, grade 3 alopecia 3.6% of pts). CONCLUSION: The results suggest that the combination of irinotecan (CPT-11) and carboplatin is active and well tolerable in patients with limited disease SCLC who were not suitable for concurrent chemotherapy.",
author = "Eckart Laack and Ina Thoem and Andreas Kr{\"u}ll and Walburga Engel-Riedel and Thomas M{\"u}ller and Christoph Meissner and Heinz D{\"u}rk and J{\"u}rgen Fischer and Sylvia G{\"u}tz and Cornelius Kortsik and Matthias Elbers and Gunter Schuch and Birte Andritzky and Michael G{\"o}rn and Iris Burkholder and Lutz Edler and Hossfeld, {Dieter Kurt} and Carsten Bokemeyer",
year = "2007",
language = "Deutsch",
volume = "57",
pages = "181--186",
journal = "LUNG CANCER",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).

AU - Laack, Eckart

AU - Thoem, Ina

AU - Krüll, Andreas

AU - Engel-Riedel, Walburga

AU - Müller, Thomas

AU - Meissner, Christoph

AU - Dürk, Heinz

AU - Fischer, Jürgen

AU - Gütz, Sylvia

AU - Kortsik, Cornelius

AU - Elbers, Matthias

AU - Schuch, Gunter

AU - Andritzky, Birte

AU - Görn, Michael

AU - Burkholder, Iris

AU - Edler, Lutz

AU - Hossfeld, Dieter Kurt

AU - Bokemeyer, Carsten

PY - 2007

Y1 - 2007

N2 - PURPOSE: The aim of this phase II trial was to evaluate the efficacy and safety of a combination chemotherapy containing irinotecan (CPT-11) and carboplatin as first-line treatment of patients with small cell lung cancer (SCLC). PATIENTS AND METHODS: From December 2002 to May 2004 61 patients with limited disease (IASLC classification) were enrolled who were not suitable for concurrent chemo-radiotherapy. Eighteen of the 61 patients (29.5%) had malignant pleural or pericardial effusion and 4 patients (6.6%) had involved supra- or infraclavicular lymph nodes. Patients received irinotecan 50mg/m(2) on days 1, 8 and 15 and carboplatin AUC 5 on day 1, every 4 weeks. RESULTS: A total of 233 chemotherapy cycles were administered. The median number of cycles per patient was 4. The overall response rate to chemotherapy on an intention-to-treat basis was 64%. The median overall survival was 13.8 months, the median disease-free survival 8.0 months, the 1-year survival rate 53.5%, and the 2-year survival rate 17.9%. Haematological and non-hematogical toxicities were low (CTC-grade 3 neutropenia 14.8%, grade 3 thrombocytopenia 5.2%, grade 3/4 anemia 5.1%, grade 3 nausea/vomiting 5.1%, grade 3 diarrhea 3.6%, grade 3 alopecia 3.6% of pts). CONCLUSION: The results suggest that the combination of irinotecan (CPT-11) and carboplatin is active and well tolerable in patients with limited disease SCLC who were not suitable for concurrent chemotherapy.

AB - PURPOSE: The aim of this phase II trial was to evaluate the efficacy and safety of a combination chemotherapy containing irinotecan (CPT-11) and carboplatin as first-line treatment of patients with small cell lung cancer (SCLC). PATIENTS AND METHODS: From December 2002 to May 2004 61 patients with limited disease (IASLC classification) were enrolled who were not suitable for concurrent chemo-radiotherapy. Eighteen of the 61 patients (29.5%) had malignant pleural or pericardial effusion and 4 patients (6.6%) had involved supra- or infraclavicular lymph nodes. Patients received irinotecan 50mg/m(2) on days 1, 8 and 15 and carboplatin AUC 5 on day 1, every 4 weeks. RESULTS: A total of 233 chemotherapy cycles were administered. The median number of cycles per patient was 4. The overall response rate to chemotherapy on an intention-to-treat basis was 64%. The median overall survival was 13.8 months, the median disease-free survival 8.0 months, the 1-year survival rate 53.5%, and the 2-year survival rate 17.9%. Haematological and non-hematogical toxicities were low (CTC-grade 3 neutropenia 14.8%, grade 3 thrombocytopenia 5.2%, grade 3/4 anemia 5.1%, grade 3 nausea/vomiting 5.1%, grade 3 diarrhea 3.6%, grade 3 alopecia 3.6% of pts). CONCLUSION: The results suggest that the combination of irinotecan (CPT-11) and carboplatin is active and well tolerable in patients with limited disease SCLC who were not suitable for concurrent chemotherapy.

M3 - SCORING: Zeitschriftenaufsatz

VL - 57

SP - 181

EP - 186

JO - LUNG CANCER

JF - LUNG CANCER

SN - 0169-5002

IS - 2

M1 - 2

ER -